Improvements in fibrosis observed using 3 pre-specified methods of histological analysis: conventional, AIM-MASH (PathAI) and qFibrosis (Histoindex)
Read more
TREE is a phase 2a clinical study assessing the safety and efficacy of lead candidate leriglitazone, a novel, brain-penetrant and selective PPAR gamma agonist, to treat patients with Rett syndrome.
Read more
ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors
Read more
Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 EPIC (EPIlepsy Cell therapy) trial as the primary basis for...
Read more
Mineralys Therapeutics today announced that it has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for the treatment of hypertension in subject...
Read more
DSMB confirms favorable safety profile of SPVN06 across all three doses in patients with severe advanced rod-cone dystrophy (RCD)
Read more
Obstructive sleep apnea represents Mineralys’ third precision, targeted indication for lorundrostat, further expanding its market potential in aldosterone-driven diseases
Read more
KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1 s...
Read more
Ysios Capital, gestora de venture capital especializada en el sector biotecnológico, y Andbank Wealth Management, gestora de fondos del banco privado Andbank, se han aliado para lanzar el Telescope B...
Read more
Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European spe...
Read more
SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations
Read more
NRTX-1001 has been well-tolerated to date at both high and low doses. No adverse events have been attributed to the cell therapy
Read more
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The research helps understand the biological basis of a rare neurodeve...
